Alcohol & Other Drug Abuse Prevention 

North Idaho College (NIC) is an Alcohol and Drug Free Education Institution.  This document describes how North Idaho College meets the requirements of the 1989 amendments to the Drug-Free Schools and Communities Act, (DFSCA), as articulated in the Education Department General Administrative Regulations, (EDGAR), Part 86 and the Drug-Free Schools and Campuses Regulations.  Specifically the DFSCA requires institutions of higher education to establish policies that address unlawful possession, use , or distribution of alcohol and illicit drugs.  It also requires the establishment of a drug and alcohol prevention program.  Students, staff, and faculty may request additional information by contacting either the Director of Student Disability, Health and Counseling ((208) 769-7794) or the Director of Student Development ((208) 769-5970).

Prevention Standards:

A.  Standards of conduct prohibit, at a minimum, the unlawful possession, use, or distribution of illicit drugs and alcohol by students and employees.  These standards of conduct govern the behavior of students, staff and faculty.  The standards of conduct shall apply to all students registered at NIC for at least one course for any type of credit with the exception for continuing education units.  Note that students who hold part time jobs within North Idaho College are covered by both student and employee policies.  The NIC standards of conduct also apply to all on-campus activities and all off-campus activities that are considered to be sponsored by NIC such as officially sanctioned field trips.  Finally, these standards of conduct will also apply to student-sponsored social activities or professional meetings attended by employees if those activities or meetings are considered to be NIC sponsored activities.  

B.  Possible sanctions and penalties under North Idaho College policy, federal, state and local laws for the unlawful possession or distribution of illicit drugs and alcohol.  Following are links to applicable policies, procedures, state, and federal code.  (Note:  there may be city ordinances that also apply to legal sanctions and penalties.  Refer to specific city codes for more information).

North Idaho College Policy 3.02.14, "Drug Free Workplace Act of 1988, 34 CFR, Part 85, Subpart F and regulations published in 1/31/89 Federal Register.

North Idaho College Procedure 3.02.14.  (Effective Date 12/22/93, revised 3/19/15)

State of Idaho Statutes, Title 18, Crimes and Punishments 

Title 21 United States Code (USC) Controlled Substances Act

C.  Health risks associated with Alcohol and Other Drug (AOD) abuse.  The following information references Title 21 United States Code (USC) Controlled Substance Act (21 U.S.C. 811).  The information describes each prohibited class of substance and the associated health risks to include the risk of dependence, possible short term effects, possible long term effects, and the effects of an overdose.

Drug Schedule Schedule Description Drug Types

Associated Health Risks

Links access the US Drug Enforcement Administration Drug Fact Sheets on each type of drug in the specific schedule

Schedule I Drugs

(1) Schedule I. -

  • (A) The drug or other substance has a high potential for abuse.

  • (B) The drug or other substance has no currently accepted medical use in treatment in the United States.

  • (C) There is a lack of accepted safety for use of the drug or other substance under medical supervision.

Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:

  • (1) Acetylmethadol.
  • (2) Allylprodine.
  • (3) Alphacetylmathadol. (FOOTNOTE 2) (FOOTNOTE 2) So in original. Probably should be ''Alphacetylmethadol.''
  • (4) Alphameprodine.
  • (5) Alphamethadol.
  • (6) Benzethidine.
  • (7) Betacetylmethadol.
  • (8) Betameprodine.
  • (9) Betamethadol.
  • (10) Betaprodine.
  • (11) Clonitazene.
  • (12) Dextromoramide.
  • (13) Dextrorphan.
  • (14) Diampromide.
  • (15) Diethylthiambutene.
  • (16) Dimenoxadol.
  • (17) Dimepheptanol.
  • (18) Dimethylthiambutene.
  • (19) Dioxaphetyl butyrate.
  • (20) Dipipanone.
  • (21) Ethylmethylthiambutene.
  • (22) Etonitazene.
  • (23) Etoxeridine.
  • (24) Furethidine.
  • (25) Hydroxypethidine.
  • (26) Ketobemidone.
  • (27) Levomoramide.
  • (28) Levophenacylmorphan.
  • (29) Morpheridine.
  • (30) Noracymethadol.
  • (31) Norlevorphanol.
  • (32) Normethadone.
  • (33) Norpipanone.
  • (34) Phenadoxone.
  • (35) Phenampromide.
  • (36) Phenomorphan.
  • (37) Phenoperidine.
  • (38) Piritramide.
  • (39) Propheptazine.
  • (40) Properidine.
  • (41) Racemoramide.
  • (42) Trimeperidine.
  • (b) Opium Derivatives

Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers, and salt of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

  •  (1) Acetorphine.
  • (2) Acetyldihydrocodeine.
  • (3) Benzylmorphine.
  • (4) Codeine methylbromide.
  • (5) Codeine-N-Oxide.
  • (6) Cyprenorphine.
  • (7) Desomorphine.
  • (8) Dihydromorphine.
  • (9) Etorphine.
  • (10) Heroin.
  • (11) Hydromorphinol.
  • (12) Methyldesorphine.
  • (13) Methylhydromorphine.
  • (14) Morphine methylbromide.
  • (15) Morphine methylsulfonate.
  • (16) Morphine-N-Oxide.
  • (17) Myrophine.
  • (18) Nicocodeine.
  • (19) Nicomorphine.
  • (20) Normorphine.
  • (21) Pholcodine.
  • (22) Thebacon.
  • (c) Hallucinogenic Substances

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

  • (1) 3,4-methylenedioxy amphetamine.
  • (2) 5-methoxy-3,4-methylenedioxy amphetamine.
  • (3) 3,4,5-trimethoxy amphetamine.
  • (4) Bufotenine.
  • (5) Diethyltryptamine.
  • (6) Dimethyltryptamine.
  • (7) 4-methyl-2,5-diamethoxyamphetamine.
  • (8) Ibogaine.
  • (9) Lysergic acid diethylamide.
  • (10) Marihuana.
  • (11) Mescaline.
  • (12) Peyote.
  • (13) N-ethyl-3-piperidyl benzilate.
  • (14) N-methyl-3-piperidyl benzilate.
  • (15) Psilocybin.
  • (16) Psilocyn.
  • (17) Tetrahydrocannabinols

Schedule II Drugs

(2) Schedule II. -

  • (A) The drug or other substance has a high potential for abuse.

  • (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.

  • (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence.

Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:

  • (1) Alphaprodine.
  • (2) Anileridine.
  • (3) Bezitramide.
  • (4) Dihydrocodeine.
  • (5) Diphenoxylate.
  • (6) Fentanyl.
  • (7) Isomethadone.
  • (8) Levomethorphan.
  • (9) Levorphanol.
  • (10) Metazocine.
  • (11) Methadone.
  • (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane.
  • (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid.
  • (14) Pethidine.
  • (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine.
  • (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate.
  • (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid.
  • (18) Phenazocine.
  • (19) Piminodine.
  • (20) Racemethorphan.
  • (21) Racemorphan.
  • (c) Methamphetamine

Unless specifically excepted or unless listed in another schedule, any injectable liquid which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers.

 

Schedule III Drugs

(3) Schedule III. -

  • (A) The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II.

  • (B) The drug or other substance has a currently accepted medical use in treatment in the United States.

  • (C) Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.

SCHEDULE III

  • (a) Stimulants

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

  • (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers.
  • (2) Phenmetrazine and its salts.
  • (3) Any substance (except an injectable liquid) which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers.
  • (4) Methylphenidate.
  • (b) Depressants

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

  • (1) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid.
  • (2) Chorhexadol.
  • (3) Glutehimide.
  • (4) Lysergic acid.
  • (5) Lysergic acid amide.
  • (6) Methyprylon.
  • (7) Phencyclidine.
  • (8) Sulfondiethylmethane.
  • (9) Sulfonethylmethane.
  • (10) Sulfonmethane.
  • (c) Nalorphine.
  • (d) Narcotic Drug

Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

  • (1) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
  • (2) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
  • (3) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
  • (4) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
  • (5) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
  • (6) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
  • (7) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
  • (8) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
  • (e) Anabolic steroids.

Schedule IV Drugs

(4) Schedule IV. -

  • (A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule III.

  • (B) The drug or other substance has a currently accepted medical use in treatment in the United States.

  • (C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III.
  • (1) Barbital.
  • (2) Chloral betaine.
  • (3) Chloral hydrate.
  • (4) Ethchlorvynol.
  • (5) Ethinamate.
  • (6) Methohexital.
  • (7) Meprobamate.
  • (8) Methylphenobarbital.
  • (9) Paraldehyde.
  • (10) Petrichloral.
  • (11) Phenobarbital.

Schedule V Drugs

(5) Schedule V. -

  • (A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV.

  • (B) The drug or other substance has a currently accepted medical use in treatment in the United States.

  • (C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.

Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

  • (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
  • (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
  • (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
  • (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
  • (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.

Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics.  Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.  Examples include cough preparations with less than 200 milligrams of codeine or per 100 milliliters Robitussin AC, Lomotil, Motofen, Lyrica, and Parepectolin.

For more information about the dangers of cough and cold medicine abuse visit the National Institute on Drug Abuse "Drug Facts: Cough and Cold Medicine Abuse" website

Additional information about Scheduled Drugs, and Tobacco/Nicotine and Alcohol, abuse and addiction can be found at the National Institute on Drug Abuse (NIH) Website.


D.  Counseling resources and drug and alcohol programs that are available to employees or students.

Idaho, Region 1 (Shoshone, Benewah, Kootenai, Bonner, and Boundary Counties), state approved drug and alcohol treatment providers can be located on the "Region 1 Treatment and RSS providers" list maintained by the Idaho Department of Health and Welfare.

Eligible North Idaho College Employees may access counseling services through the NIC Employee Assistance Program.  To check eligibility, contact the Human Resources office.  Information about the EAP program and how to gain counseling services can be found on the NIC Benefits Links webpage under "Reliant Behavioral Health.."  Also, other health and counseling services may be available to you through your health insurance program.  Contact NIC Human Resources or your health insurance provider for additional information.  

NIC Students may access counseling services and receive community referrals through the North Idaho College Student Counseling program by calling (208) 769-3362.

The Idaho Department of Health and Welfare, Division of Behavioral Health Substance Use Disorder Service Program can provide assistance with alcohol or drug problems.  Call (800) 922-3406 for a screening and referral to an approved treatment facility. The amount paid depends on your financial situation.

Substance Abuse and Mental Health Services Administration (SAMHSA).  This organization is responsible for overseeing and administering mental health, drug prevention, and drug treatment programs around the nation.  the Center for Substance Abuse Prevention (CSAP) and the Center for Substance Abuse Treatment (CSAT) are part of SAMHSA.

National Institute on Drug Abuse (NIDA).  NIDA conducts and disseminates the results of research about the effects of drugs on the body and the brain.  NIDA is an excellent source of information on drug addiction. 

Other resources include:

E.  Drug and Alcohol Prevention Biennial Review Reports.  The Drug-Free Schools and Campuses Regulations requires North Idaho College to conduct a biennial review of the "Drug and Alcohol Abuse Prevention" effectiveness and consistency.  The Biennial Reviews will be conducted at the end of each even-numbered calendar years.

 Review Year  Drug and Alcohol Prevention Biennial Review Report
 2015/2016      January 2017 -
NIC 2015-2016 Alcohol and Other Drug Biennial Report
 2017/2018  Due January 2019
 2019/2021  Due January 2021
 

F.  Annual Notification.  North Idaho College is required to notify all students and employees annually regarding specific drug and alcohol related information.  A link to the webpage content will be sent to all North Idaho College Staff and Faculty annually no later than January 30th each year.  A link to the webpage content will also be sent to all North Idaho College registered students no later than the first day of each semester, (spring semester, summer semester, fall semester). 

 Year  

 

Staff & Faculty
Notification Date
(Annual)

 

Spring Semester 
Notification Date
(Student)

 

 

Fall Semester Notification Date
(Student)
 2016  01-14-2016  01-12-2016    08-31-2016
 2017  01-18-2017  01-18-2017    09-21-2017
 2018        
 2019        
 

(This page is maintained and updated by the North Idaho College Student Services Division on at least an annual basis.  If you have questions, please contact the Director of Student Disability, Health and Counseling at (208) 769-7794 or (208) 665-4520).
1-8-2016 Content was reviewed for accuracy, (annual review).  T. Gerlitz, Director